1,033 results on '"Morra, Enrica"'
Search Results
102. Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia
103. Clonal architecture ofCXCR4WHIM-like mutations in Waldenström Macroglobulinaemia
104. The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability
105. Long Term Toxicity and Follow-up of Waldenstrom´s Macroglobulinemia Patients after Salvage Treatment with Fludarabine Cyclophosphamide Rituximab or Bendamustine and Rituximab
106. GEP Analyses of Bone Marrow CD34+/Lin- Cells of Chronic Phase CML Patients at Diagnosis Identified Different Sets of Genes Associated to the Molecular Response after 3 and 6 Months of First-Line Nilotinib Treatment
107. REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data
108. Efficacy and tolerability of treatment with line II nilotinib in a patient with coronary artery disease
109. Erythroleukemia presenting with myeloid sarcoma of the lung as detected by immunophenotypic analysis of bronchoalveolar lavage fluid
110. Down-regulation of MicroRNAs 222/221 in Acute Myelogenous Leukemia with Deranged Core-Binding Factor Subunits12
111. Abstract 5491: Sequential use of first and second generation TKIs are effective on prolonged overall survival in elderly population affected by Ph+ acute lymphoblastic leukemia: the GIMEMA experience
112. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia
113. Feasibility of Romiplostim Discontinuation in Adult Thrombopoietin-Receptor Agonist Responsive Patients with Primary Immune Thrombocytopenia: An Observational Retrospective Report in Real Life Clinical Practice
114. Autologous stem cell transplantation within vivopurged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma
115. Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report
116. Direct Healthcare Costs of Treated Multiple Myeloma: Results from a Population-Based Study
117. Gene Expression Profiling of IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS)
118. Danazol Treatment in Lower Risk MDS Patient with Severe Thrombocytopenia: A Monocentric Experience
119. Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML
120. Bendamustine and Rituximab Combination Is Safe and Effective As Salvage Regimen in Waldenstrom's Macroglobulinemia
121. Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients
122. Low Risk IPSS/DIPSS Primary Myelofibrosis: Identification of Patients with Higher Risk of Progression
123. Survival of Allogeneic Stem Cell Transplantation Vs Conventional Therapies per DIPSS Stratification in Patients with Primary Myelofibrosis Younger Than 65 Years: A Retrospective Analysis on 673 Patients
124. Microarray of Bone Marrow CD34+/Lin- Cells from Patients with Chronic Myeloid Leukemia (CML)
125. Treated Multiple Myeloma Patients: Demographic Characteristics, Incidence Rate and Mortality in Lombardy during the 2003-2009 Period
126. Gene Expression Profiling of CD34+/Lin- Cells of Patients with Chronic Myeloid Leukemia at Diagnosis and after 12 Months of Nilotinib
127. Transcriptome-Wide Analysis of Bone Marrow CD19+ Cells As Well As Bone Marrow B Cell Clones of Waldenström's Macroglobulinemia (WM) Vs. IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS)
128. Prognostic relevance of the flow cytometric count of medullar blasts in myelodysplastic syndromes
129. Overview on clinical trials in Waldenstrom's macroglobulinemia
130. Abstract 5552: Extremely high rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by innovative sequential use of Nilotinib and Imatinib. A GIMEMA Protocol LAL 1408
131. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia
132. Strategies for the transfusion of subjects with complex red cell immunisation: the Bank of rare blood donors of the Region of Lombardy
133. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia
134. Colla di fibrina homemade e commerciale in chirurgia epatica
135. A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM)
136. Carfilzomib: a new opportunity for WM patients
137. Invasive fungal infections in lymphoproliferative disorders: a monocentric retrospective experience
138. Corrigendum to ‘Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: The experience of the “Rete Ematologica Lombarda”’ [Leuk Res 37 (2013) 1233–1240]
139. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
140. From the Second International VVorkshop on Waldenstrom's Macroglobulinemia
141. Characterization Of Genes and Pathways From The Comparison Between Bone Marrow B Cells As Well As Plasma Cells Of Waldenström Macroglobulinemia (WM) Vs. IgM Monoclonal Gammopathy Of Undetermined Significance (IgM-MGUS) Vs. Healthy Subjects Using Gene Profiling
142. Impact Of Ruxolitinib On The Natural History Of Patients With Primary Myelofibrosis: A Retrospective Comparison Of The DIPSS and The Comfort-2 Cohorts
143. Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias
144. A Phase II Multi-Center Trial Of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) In Older Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients
145. Non-Hodgkin's Lymphomas Associated With Positive Hepatitis-C Virus Infection: A Prospective Multicentric Observational Study On Behalf Of The “Rete Ematologica Lombarda/Hematology Network Of Lombardia Region”
146. Total serum tryptase: A predictive marker for KIT mutation in acute myeloid leukemia
147. Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects
148. Rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by sequential use of nilotinib and imatinib: A GIMEMA protocol LAL 1408.
149. Regeneration-associated WNT Signaling Is Activated in Long-term Reconstituting AC133bright Acute Myeloid Leukemia Cells
150. ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.